Study to Compare the Efficacy & Safety of Ursoplus Capsules vs. UDCA vs. Placebo Among Chronic Liver Disease Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

297 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-22

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to compare the efficacy \& safety of Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg) versus UDCA alone versus Placebo among Compensated Chronic Liver Diseased Patients

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis

NCT01510860

Primary Biliary Cirrhosis

COMPLETED PHASE4

Evaluation of PK and Biomarkers After UDCA Administrations to Subjects Who Are Overweight and Have Liver Problems

NCT03000218

Overweight Abnormal Liver Function Tests

UNKNOWN PHASE1

Pilot Study of Ursodesoxycholic Acid in Non-Alcoholic Steatohepatitis

NCT00470171

Serum Levels of ALAT Transaminases Serum Markers for Fibrosis and Hepatic Inflammation

COMPLETED PHASE2

Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response

NCT07102979

Liver Cirrhosis

ENROLLING_BY_INVITATION NA

Safety And Efficacy Study Of Orally Administered Epeleuton In Patients With NAFLD

NCT02941549

Non Alcoholic Fatty Liver Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Research Question:

Compare the efficacy \& safety of Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg) versus UDCA alone versus Placebo among Compensated chronic liver diseased patients

Primary Objective:

To assess the efficacy of Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg) versus UDCA 250mg alone and versus Placebo in the reduction of total serum bilirubin, Direct serum bilirubin and elevated liver Enzymes from baseline to End of Treatment (EOT)

Secondary Objectives:

* To assess the efficacy of Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg) versus UDCA 250 mg alone and versus Placebo in reducing the degree of steatosis as measured by Vibration-controlled transient elastography with Controlled Attenuation Parameter (CAP)
* To assess the safety of Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg) versus UDCA 250 mg alone and versus Placebo among compensated Chronic Liver Diseased Patients
* To describe improvement in quality of life for patients after treatment

A study population of 297 patients suffering from compensated chronic Liver Disease, who will be randomized according to Vibration-controlled transient elastography in screening visit into 2 groups:

* Group 1: with non-cirrhosis, F0, F1 and F2.
* Group 2: with advanced fibrosis and cirrhosis, F3 and F4.

Each group will receive either Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg), or UDCA alone or Placebo, through Stratified random sampling.

Duration for enrollment: 6 months Total duration of the study/subject will be approximately: 6 months for treatment and follow-up visits including the screening visit

Subjects will be enrolled for a duration of 6 months including the screening visit

* Screening visit 1 (Treatment initiation)
* Visit 2: after 1st month, follow-up 1
* Visit 3: after 2nd month, follow-up 2
* Visit 4: after 3rd month, follow-up 3
* Visit 5: after 4th month, follow-up 4
* Visit 6: after 5th month, follow-up 5
* End of Study visit, after 6th month of treatment, follow-up 6

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Liver Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Group 1: with non-cirrhosis, F0, F1 and F2 Group 2: with advanced fibrosis and cirrhosis, F3 and F4

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ursoplus® capsules (UDCA 250mg & Silymarin 140mg)

Ursoplus® capsules: UDCA 250mg \& Silymarin 140mg

2 Capsules every 12 hours

Group Type EXPERIMENTAL

Ursoplus

Intervention Type DRUG

Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg)

UDCA 250mg

UDCA capsules: UDCA 250mg

2 Capsules every 12 hours

Group Type ACTIVE_COMPARATOR

UDCA 250mg

Intervention Type DRUG

UDCA 250mg alone

Placebo

Placebo alone

2 Capsules every 12 hours

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo alone

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ursoplus

Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg)

Intervention Type DRUG

UDCA 250mg

UDCA 250mg alone

Intervention Type DRUG

Placebo

Placebo alone

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female patients aged ≥ 18
2. Subjects with Compensated Chronic Liver Disease, defined as child 5-7.
3. Patients with mild disturbance of liver biochemical profile (elevated Total Serum Bilirubin ≤ 3 mg/dl, or elevated Direct Serum Bilirubin ≤ 2 mg/dl, or elevated one or more of liver enzymes, up to 3 times of the normal level (Alanine Transaminase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) \& Gamma Glutamyl Transpeptidase (GGT)).
4. Non-diabetic subjects and subjects with Controlled DM-type 1 and 2 patients, HbA1C up to 7.5%
5. Non-pregnant or lactating female patients
6. Subjects who are willing to sign Informed Consent Form (ICF) and ready to comply with the protocol for the duration of the study

Exclusion Criteria

1. Subjects with a history of hypersensitivity to any of the ingredients of the medications being studied
2. Subjects with positive PCR/or antibodies to Hepatitis C in the past 6 months
3. Subjects with positive hepatitis B surface antigen (HBsAg)
4. Subjects with elevated liver enzymes more than 3 times of the normal level Alanine Transaminase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) \& Gamma Glutamyl Transpeptidase (GGT).
5. Subjects with Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC).
6. Subjects with Child Pugh Score more than 7.
7. Subjects with history of bleeding varices.
8. Subjects having uncontrolled Diabetes (HbA1cmore than 7.5 %)
9. Subjects with any medical condition requiring the usage of medication that may interfere with the absorption, distribution, metabolism or excretion of the study drug such as:

1. Bile acid sequestering agents such as cholestyramine and colestipol.
2. Antacids containing aluminum hydroxide.
3. Drugs affecting lipid metabolism such as estrogens, oral and hormonal contraceptives, and clofibrate (and perhaps other lipid-lowering drugs)
10. Subjects who are receiving other liver support drugs (including drugs of the study), 1 month before study initiation.
11. Subjects with auto immune liver disease taking corticosteroid or immune suppressant
12. Pregnant or breast-feeding women
13. Use of oral contraceptives in child bearing ladies

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No